FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
01/10/2025
Back to search
Official data from USPTO
ARGORNA
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
28
Latest update
01/11/2025
Trademark type
Combined
Nice classes
5
Filing date
12/06/2022
Registration date
07/09/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/09/2024
Last transaction
01/11/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
5
Owner type
99
Owner location
CN
Examiner
BLANDU, FLORENTINA
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
ARGORNA PHARMACEUTICALS CO., LTD
Representatives
Victoria Friedman Dennemeyer & Associates, LLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of tumorasthmaarthritisviral diseasesrespiratory diseasesinflammationfibrosishypertensionhyperlipidemiacardiovascular diseaseseye diseasesanginadiabetesinsomnia; vaccines; drugs for medical purposespharmaceuticals for the treatment of tumorasthmaarthritisviral diseasesrespiratory diseasesinflammationfibrosishypertensionhyperlipidemiacardiovascular diseaseseye diseasesanginadiabetesinsomnia; biological preparations for medical purposesfor the treatment of tumorasthmaarthritisviral diseasesrespiratory diseasesinflammationfibrosishypertensionhyperlipidemiacardiovascular diseaseseye diseasesanginadiabetesinsomnia; medicines for human purposes; diagnostic preparations for medical purposes; chemical reagents for medical or veterinary purposes; reagent paper for medical purposes; raw material medicineinsulin; biochemical medicines for the treatment of tumorasthmaarthritisviral diseasesrespiratory diseasesinflammationfibrosishypertensionhyperlipidemiacardiovascular diseaseseye diseasesanginadiabetesinsomnia
Publications
History of USPTO decisions and trademark events.
28 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
12/20/2024
FIMP
FINAL DISPOSITION PROCESSED
12/20/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/09/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/09/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2024
GPNX
NOTIFICATION PROCESSED BY IB
04/30/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/23/2024
PUBO
PUBLISHED FOR OPPOSITION
04/23/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/10/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/10/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/03/2024
RFNT
REFUSAL PROCESSED BY IB
03/18/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/16/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/14/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/14/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/14/2024
CNRT
NON-FINAL ACTION MAILED
02/02/2024
CNRT
NON-FINAL ACTION WRITTEN
01/11/2024
RFNT
REFUSAL PROCESSED BY IB
10/17/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/28/2023
RFRR
REFUSAL PROCESSED BY MPU
09/28/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/18/2023
CNRT
NON-FINAL ACTION WRITTEN
09/17/2023
DOCK
ASSIGNED TO EXAMINER
09/13/2023
MAFR
APPLICATION FILING RECEIPT MAILED
05/09/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/05/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
05/04/2023
Continuous trademark protection
Get notified about every new filing that threatens ARGORNA or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.